Neurovalens creates non-invasive medical devices that solve some of the world’s greatest health challenges. Their neurostimulation technology enables modulation of autonomic function, circadian regulation and neuro-metabolic influence. The technology aims to provide drug-free solutions to the world’s greatest health epidemics, such as obesity and type II diabetes.
IQ Capital first invested in Neurovalens at seed stage in 2019 and Series A in 2020.
"The benefit of having IQ Capital as part of the team extends well beyond providing funding. I am extremely grateful for the sense of ambition and passion that IQ Capital see in the future of Neurovalens. If you have an exciting idea and are ready to move fast, then I would highly recommend reaching out the IQ team and finding out more about how they can help your company succeed."